SEHK:1672Biotechs
Assessing Ascletis Pharma (SEHK:1672) Valuation After ASC30_39 Obesity Candidate Advances Toward FDA IND Filing
Ascletis Pharma (SEHK:1672) announced the selection of its ASC30_39 fixed dose combination obesity therapy candidate for clinical development. The company plans to file an IND with the U.S. FDA in the third quarter of 2026.
See our latest analysis for Ascletis Pharma.
That obesity announcement comes after a strong run in the shares, with the latest price at HK$18.48, a 30 day share price return of 25.03% and a 1 year total shareholder return of 274.09%. This suggests momentum has been...